/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a.
Astellas' XTANDItm (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Today (April 24), Astellas Pharma Inc. revealed that XTANDITM (enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC) treatment in the European Union (EU).
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.